The Effects of Standard Anthracycline-Based Chemotherapy on Soluble ICAM-1 and Vascular Endothelial Growth Factor Levels in Breast Cancer
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Purpose: The circulating soluble form of intercellular adhesion molecule-1 (sICAM-1) and vascular endothelial growth factor (VEGF) are elevated in women with breast cancer and associated with tumor progression and poor prognosis. This study examined the effects of anthracycline-based chemotherapy on plasma sICAM-1 and VEGF, as well as soluble P-selectin, von Willebrand factor, and interleukin-6 levels. Experimental Design: Twenty-six women diagnosed with stage I–IIIA breast cancer (mean age, 48.4 ± 10.4 years; range, 34–79 years) were studied before (week 1) and at weeks 2 and 3 of cycles 1 and 4 of chemotherapy. Results: The initial effect of chemotherapy was to reduce sICAM-1 levels; compared with pretreatment, sICAM-1 levels were decreased at week 2 of both cycles (P values < 0.01). sICAM-1 levels were elevated, however, at the start of cycle 4 as compared with pretreatment (P < 0.01). Chemotherapy led to an increase in sICAM-1 levels in node-positive but not node-negative patients (P < 0.01). VEGF levels were decreased at week 2 of cycle 4 (P = 0.001) and remained so at week 3. Similar to sICAM-1, VEGF levels were elevated at the start of cycle 4 as compared with pretreatment (P < 0.006). Soluble P-selectin levels decreased during week 2 of cycle 4 (P = 0.026). Neither interleukin-6 or von Willebrand factor were significantly changed in response to chemotherapy. Conclusions: The findings support prior studies suggesting that sICAM-1 levels derive from sources other than endothelial cells. In addition, whereas the more immediate effect of chemotherapy is to reduce sICAM-1 and VEGF, continued treatment may lead to significant elevations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes
Tsavaris, N., Kosmas, C., Vadiaka, M., Kanelopoulos, P., & Boulamatsis, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600347 · Cited by 343 · cited 1×
“Other studies with high-dose chemotherapy and with taxanes indicate that the proinflammatory cytokines IL-6 and tumor necrosis factor may be increased in response to certain treatment regimes (26, 27).”
Background
Cited by
Cancer-related fatigue—mechanisms, risk factors, and treatments
Bower, J. E. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.127 · Cited by 1,666
Neuroendocrine-Immune Mechanisms of Behavioral Comorbidities in Patients With Cancer
Miller, A. H., Ancoli-Israel, S., Bower, J. E., Capuron, L., & Irwin, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7805 · Cited by 608
Self-citationCircadian Rhythms: Mechanisms and Therapeutic Implications
Levi, F., & Schibler, U. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105208 · Cited by 645
Bower, J. E., Ganz, P. A., Irwin, M. R., Kwan, L., Breen, E. C., & Cole, S. W. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1154 · Cited by 486
Bower, J. E., & Lamkin, D. M. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.06.011 · Cited by 372
Metadata
- Authors
- Mills, P. J., Parker, B., Jones, V., Adler, K. A., Perez, C. J., Johnson, S., Cohen-Zion, M., Marler, M., Sadler, G. R., Dimsdale, J. E., & Ancoli-Israel, S.
- Venue
- Clinical Cancer Research
- Published
- 2004-08-01
- Volume
- 10
- Issue
- 15
- Pages
- 4998-5003
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2116636243
- Cited by
- 74
- References
- 1
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effects of Standard Anthracycline-Based Chemotherapy on Soluble ICAM-1 and Vascular Endothelial Growth Factor Levels in Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-0734-04
- The paper
- Mills, P. J., Parker, B., Jones, V., Adler, K. A., Perez, C. J., Johnson, S., Cohen-Zion, M., Marler, M., Sadler, G. R., Dimsdale, J. E., & Ancoli-Israel, S. (2004). The Effects of Standard Anthracycline-Based Chemotherapy on Soluble ICAM-1 and Vascular Endothelial Growth Factor Levels in Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-0734-04
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.